Published in Eur J Biochem on August 15, 1993
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Interleukin-6: structure-function relationships. Protein Sci (1997) 1.59
Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J (1995) 1.39
Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun (1996) 1.05
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc Natl Acad Sci U S A (2002) 1.04
Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A (1996) 1.02
The DEAD-box helicase DDX3 supports the assembly of functional 80S ribosomes. Nucleic Acids Res (2012) 1.00
Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells. J Clin Invest (1997) 0.87
Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO J (1996) 0.79
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling. Rheumatol Int (2008) 0.77
Arginine inhibits adsorption of proteins on polystyrene surface. PLoS One (2013) 0.75
Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol (1993) 3.37
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (1990) 3.27
GroE facilitates refolding of citrate synthase by suppressing aggregation. Biochemistry (1991) 2.92
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett (1989) 2.79
Control of proteolysis. Annu Rev Biochem (1980) 2.67
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett (1988) 2.39
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol (1994) 2.26
Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem (1996) 2.19
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem (2000) 2.14
Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett (1987) 2.04
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol (1988) 1.95
Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol (2006) 1.95
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y) (1991) 1.88
A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme. Biochemistry (1991) 1.83
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
Action of recombinant human interleukin 6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute-phase proteins. Eur J Immunol (1988) 1.76
Advances in refolding of proteins produced in E. coli. Curr Opin Biotechnol (1998) 1.75
Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest (2001) 1.71
The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol (1994) 1.70
A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol (1995) 1.70
TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol (1999) 1.69
Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem (1988) 1.69
Circular dichroism of ribonucleoprotein complexes from rat liver nuclei. Biochem Biophys Res Commun (1977) 1.69
Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am J Pathol (1991) 1.69
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol (1994) 1.67
Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology (N Y) (1991) 1.65
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
An evaluation of 2,5-norbornadiene as a reversible inhibitor of ethylene action in deepwater rice. Plant Physiol (1987) 1.60
Fluorescence in situ hybridization shows spatial distribution of as yet uncultured treponemes in biopsies from digital dermatitis lesions. Microbiology (1998) 1.55
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol (1997) 1.51
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
Reconstitution of lactic dehydrogenase. Noncovalent aggregation vs. reactivation. 1. Physical properties and kinetics of aggregation. Biochemistry (1979) 1.49
Refolding and association of oligomeric proteins. Methods Enzymol (1986) 1.47
A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem (1996) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol (1999) 1.45
The ultrastructure of chronic radiation damage in rat skin. Surg Gynecol Obstet (1981) 1.43
STAT3 is constitutively activated in Hodgkin cell lines. Blood (2001) 1.42
Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Cancer Invest (2000) 1.39
A modest proposal to (maybe) avoid cervical disc disease. Plast Reconstr Surg (1998) 1.39
The accuracy of free-hand cup positioning--a CT based measurement of cup placement in 105 total hip arthroplasties. Int Orthop (2004) 1.38
A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22. Am J Hum Genet (1999) 1.37
Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther (1997) 1.36
Effect of swainsonine on the processing of the asparagine-linked carbohydrate chains of alpha 1-antitrypsin in rat hepatocytes. Evidence for the formation of hybrid oligosaccharides. J Biol Chem (1983) 1.35
Fournier's syndrome: synergistic gangrene of the scrotum. Am J Surg (1975) 1.35
Reconstitution of a heat shock effect in vitro: influence of GroE on the thermal aggregation of alpha-glucosidase from yeast. Biochemistry (1991) 1.34
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 1.32
Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem (2000) 1.32
Tumor induction by human adenovirus type 12 in hamsters: loss of the viral genome from adenovirus type 12-induced tumor cells is compatible with tumor formation. EMBO J (1982) 1.31
Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem (1988) 1.31
STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut (2006) 1.30
Analysis of the reconstitution of oligomeric enzymes by cross-linking with glutaraldehyde: kinetics of reassociation of lactic dehydrogenase. Biochemistry (1981) 1.28
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J (1998) 1.28
1-deoxynojirimycin impairs oligosaccharide processing of alpha 1-proteinase inhibitor and inhibits its secretion in primary cultures of rat hepatocytes. J Biol Chem (1983) 1.27
Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology (1996) 1.26
Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction. FEBS Lett (1995) 1.26
Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest (1995) 1.25
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene (1999) 1.24
The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. Biochemistry (2000) 1.23
The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem (2001) 1.22
The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw (2000) 1.21
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology (2007) 1.20
In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol (1998) 1.19
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Reversible high-pressure dissociation of lactic dehydrogenase from pig muscle. Biochemistry (1980) 1.19
Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem (1993) 1.18
Identification of the promoter sequences involved in the interleukin-6 dependent expression of the rat alpha 2-macroglobulin gene. Nucleic Acids Res (1989) 1.17
Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol (1995) 1.16
The refined structures of a stabilized mutant and of wild-type pyruvate oxidase from Lactobacillus plantarum. J Mol Biol (1994) 1.15
Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain (2005) 1.15
The development of stimulus control with and without a lighted key. J Exp Anal Behav (1972) 1.14
Messenger RNA activities of four acute phase proteins during inflammation. FEBS Lett (1983) 1.14
Silicon identification in prosthesis-associated fibrous capsules. Science (1978) 1.13
Rapid and efficient inactivation of IL-6 gingipains, lysine- and arginine-specific proteinases from Porphyromonas gingivalis. Biochem Biophys Res Commun (1999) 1.13
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol (1998) 1.13
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Folding of a synthetic parallel beta-roll protein. FEBS Lett (2000) 1.13
Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia (1999) 1.12
A fusion protein designed for noncovalent immobilization: stability, enzymatic activity, and use in an enzyme reactor. Nat Biotechnol (1996) 1.12